SPONSOR
Eli Lilly and Company
Total Trials
13
Recruiting
13
Phases
Phase 3, Phase 2, Phase 1, Phase 4
Conditions studied: Ulcerative ColitisAsthmaHealthyAlcohol Use DisorderObesityOverweightBreast NeoplasmsColorectal NeoplasmsProstate NeoplasmEndometrial Neoplasms
NCT05784246 Phase 3
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Ulcerative Colitis
NCT07219173 Phase 2
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Asthma
NCT07346495 Phase 1
Recruiting
A Study of Remternetug (LY3372993) in Healthy Chinese Participants
Healthy
NCT07219966 Phase 3
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Alcohol Use Disorder
NCT06972459 Phase 3
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Obesity
NCT07114601 Phase 1
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Breast Neoplasms
NCT07006792 Phase 4
Recruiting
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Atopic Dermatitis
NCT07215312 Phase 2
Recruiting
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Diabetes Mellitus, Type 2
NCT06897475 Phase 2
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Type 2 Diabetes
NCT07353931 Phase 3
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Osteoarthritis
NCT06586515 Phase 1
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Pancreatic Ductal Adenocarcinoma
NCT07241390 Phase 3
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Atherosclerosis Cardiovascular Disease
NCT06339008 Phase 3
Recruiting
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Perennial Allergic Rhinitis (PAR)